TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis

Dan Cristian Gheorghe 1, Marcel Marian Stanciu 2, Anca Zamfirescu 3 and Adina Elena Stanciu 4,*  

1 ENT Department, University of Medicine and Pharmacy Carol Davila Bucharest, 050474 Bucharest, Romania; gheorghe.dancristian@gmail.com  
2 Electrical Engineering Faculty, University Politehnica of Bucharest, 060042 Bucharest, Romania; marcel.stanciu@upb.ro  
3 Department of Radionuclide Therapy, Institute of Oncology Bucharest, 022328 Bucharest, Romania; ancacvi@gmail.com or ancamzamfirescu@gmail.com  
4 Department of Carcinogenesis and Molecular Biology, Institute of Oncology Bucharest, 022328 Bucharest, Romania  
* Correspondence: adinaelenastanciu@yahoo.com

Abstract: Autoimmune thyroiditis (AIT) may impair the uptake of radioiodine (131I), altering the success of attempted remnant ablation in papillary thyroid cancer (PTC), but the cause is not clear. Finding the mechanisms that govern immune cells during the 131I therapy of PTC with concomitant AIT (PTC + AIT) could provide a rationale. Our study aimed to evaluate the effects of 131I on anti-thyroglobulin antibodies (TgAb), matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor TIMP-1 and tumor necrosis factor-α (TNF-α) and its receptors TNFR1 and TNFR2, in PTC and PTC + AIT patients. Peripheral blood was collected from 56 female patients with PTC and 32 with PTC + AIT before and 4 days after 131I (3.7 GBq). The serum levels of TgAb, MMP-9, TIMP-1, TNF-α, TNFR1 and TNFR2 were measured by ELISA. The mean radioactivity of blood samples collected after 131I intake was higher in the PTC + AIT group than in PTC (p < 0.001). In the PTC + AIT group, TNF-α/TNFR1 and TNF-α/TNFR2 ratios decreased by 0.38-fold and 0.32-fold after 131I and were positively correlated with the MMP-9/TIMP-1 ratio (r = 0.48, p = 0.005, and r = 0.46, p = 0.007). In the PTC group, TNF-α/TNFR1 and TNF-α/TNFR2 ratios increased by 3.17-fold and 3.33-fold and were negatively correlated with the MMP-9/TIMP-1 ratio (r = −0.62, p < 0.001 and r = −0.58, p < 0.001). Our results demonstrate that TNF-α may exert different antitumor effects in response to 131I therapy depending on the patient’s immune profile.

Keywords: papillary thyroid cancer; autoimmune thyroiditis; 131I; TgAb; TNF-α; TNFR

1. Introduction

Increasing evidence shows an alarming and unexplained rise in autoimmune conditions over the past 30 years. Autoimmune diseases (AIDs) represent a wide range of disorders manifested by inflammation of organs due to the production of antibodies against self-structures and the cytotoxic action of T cells. For different AIDs, the incidence is rising between 3% and 9% per year [1]. Chronic lymphocytic thyroiditis has shown a 6% increase...
per year, with a female preponderance of ≥85% [1]. Although current therapies for AIDs aim to inhibit immune cell activation and effector immune pathways, including those activated by cytokines and cytokine receptors [2], in the case of autoimmune thyroiditis (AIT), treatment does not follow this direction. Patients with high titers of thyroid peroxidase antibodies (anti-TPO) or anti-thyroglobulin antibodies (TgAb) but with thyroid function tests in the normal range do not require treatment. On the other hand, AIT features are independent risk factors for PTC development. The association between AIT, papillary thyroid cancer (PTC) and MALT lymphoma is the main topic of case reports [3]. Compared to the general population, patients with AIT have a three-fold higher risk of developing PTC [3,4], accounting for approximately 80% of all thyroid cancers. The coexistence of the two conditions has been reported in many studies [3–6]. However, regardless of the presence or absence of AIT, the treatment is the same, consisting of thyroidectomy followed by radioactive iodine (131I) ablation of the postsurgical thyroid remnant [6]. The radionuclide 131I emits beta radiation for intracellular therapy and gamma radiation for defining the presence or absence of remnant thyroid tissue. As all patients have some remnant thyroid tissue after thyroidectomy, strong uptake of 131I into the thyroid bed is a prerequisite for remnant ablation. However, due to the toxicity of 131I, the focus should be on using the minimum effective dose. Recent evidence shows that concomitant AIT in PTC is associated with a better outcome and lower recurrence rates [4,7]. However, after analyzing the effect of the presence or absence of thyroiditis and different activities of 131I administered to a population with differentiated thyroid cancer over a period of three years, Lim et al. reported that concurrent AIT may impair the uptake of 131I, altering the success of attempted remnant ablation [8], but the cause is not clear. Finding the mechanisms that govern immune cells during the 131I therapy of PTC with concomitant AIT could provide a rationale for these reports.

Recent data have suggested that radiation therapy may modulate antitumor immune responses [9] and induce changes in the local microenvironment, affecting tumor development [10] and not only through “danger” signals that propagate from irradiated to non-irradiated cells [11,12]. The expression of TNF-α is increased after irradiation and may be involved in non-targeted effects, especially in bystander signaling in non-irradiated cells within or in the vicinity of the irradiated area, either via intercellular gap junctions or medium transfer mechanisms along with matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) [13]. It is well known that the tumor necrosis factor-alpha (TNF-α) precursor is cleaved to release soluble TNF-α to increase apoptosis in response to high-dose radiation of tumors [14]. Further, TNF-α can be slowly cleaved from the cell surface by MMPs, producing a bioactive cytokine, soluble TNF-α, which may increase apoptosis through binding to TNF receptor type 1 (TNFR1) [15]. Specifically, our purpose was to evaluate the effects of therapeutic irradiation with 131I on the serum levels of TgAb, MMP-9 and its tissue inhibitor TIMP-1 and TNF-α and its receptors TNFR1 and TNFR2, in PTC and PTC associated with AIT (PTC + AIT) patients.

2. Materials and Methods

2.1. Patients and Study Protocol

Fifty-six female patients with PTC (mean age 43.2 ± 12.7 years) and 32 with PTC associated with AIT (mean age 40.6 ± 12.3 years) were admitted for 131I therapy in the Department of Radionuclide Therapy of the Institute of Oncology Bucharest. All PTC with/without AIT patients enrolled in the study were treated with total thyroidectomy, followed by the ablation of residual active tissue in the thyroid bed with an oral dose of ThyroTop131, with an average activity around 100 mCi (3.7 GBq) of 131I. 131I sodium iodide ThyroTop is a radiopharmaceutical and was purchased from Institute of Isotopes Co. Ltd. (IZOTOP), Budapest, Hungary. Indication for 131I therapy in this cohort of patients was based on the recommendation from guidelines developed by the European and American Thyroid Associations (ETA and ATA) [16,17] in compliance with safety measures [18]. PTC + AIT patients had positive TgAb antibody titers. The exclusion criteria
were as follows: (i) age under 18 years; (ii) acute infection, burning, pulmonary, hepatic or renal impairment; (iii) ongoing treatment with steroidal or non-steroidal anti-inflammatory drugs; (iv) ongoing treatment with antibiotics from the tetracycline group, especially doxycycline (known as MMP inhibitors) [19]. For each enrolled patient, a detailed medical and drug history was obtained. All patients underwent a physical examination and routine laboratory tests. The study protocol consisted of serum TgAb, MMP-9, TIMP-1, TNF-α, TNFR1 and TNFR2 measurements in PTC patients with/without AIT (before and 4 days after the therapeutic dose of $^{131}$I administration).

The study was conducted following the principles outlined in the Declaration of Helsinki and was approved by the Institute of Oncology Bucharest Medical Ethics Committee (No.15140/10.09.2019). Signed informed consents were obtained from all patients.

2.2. Histopathology

Clinical and histopathological data were collected from patients’ medical records. AIT diagnosis is a complex and difficult issue because morphological and serological reports are not always interchangeable, recording different degrees of glandular destruction [20]. The diagnosis criteria for AIT were as follows: (i) background inflammatory infiltrate in the non-neoplastic thyroid (significant numbers of lymphocytes infiltrating the normal thyroid parenchyma away from the neoplastic process; lymphocytes are predominantly T cells and plasma cells—polyclonal); (ii) presence of secondary lymphoid follicles with germinal centers; (iii) atrophic thyroid follicles with minimal colloid, lined by Hürthle cells (metaplastic follicular epithelial cells having abundant eosinophilic cytoplasm and round to oval nuclei with nucleoli); (iv) high titers of TgAb [20,21]. Isolated peri- and intra-tumoral lymphocytic infiltration was not considered as AIT. AIT was preoperatively excluded in all patients in the PTC group. Assessment of the clinical stage was based on the eighth edition of the American Joint Committee on Cancer (AJCC)/TNM cancer staging system (2018) [22]. All the patients enrolled in the study had the classic form of PTC.

2.3. Blood Sampling

Fasting blood specimens were collected by venipuncture into BD Vacutainer SST™ II Advance tubes with clot activator (silica particles) right before the start of treatment ($^{131}$I administration) and 4 days after. Blood samples were allowed to clot for 30 min at room temperature before centrifugation for 15 min at 1000 × g. Then, the serum samples were aliquoted into labeled cryo-vials and stored at −80 °C for further analysis.

It should be noted that blood samples collected 4 days after $^{131}$I intake were radioactive. A separate procedure for harvesting, transporting, processing and storing radioactive biological samples was prepared. This procedure complies with the rules in force from the European Association of Nuclear Medicine (EANM) guidelines [23] and ISO 15189: 2013/ISO 15190: 2005 (requirements for quality and competence in medical laboratories/requirements for safety in medical laboratories). Blood activity was measured, with a microcurie accuracy, in a dose calibrator (CURIEMENTOR® 3 Isotope Calibrator, PTW Freiburg, Germany). Background count was measured without blood samples before the measurement of activity of each blood sample.

2.4. Biomarker Measurements

The ELISA kits required for the quantitative determination of serum MMP-9, TIMP-1, TNF-α, TNFR1 and TNFR2 concentrations were purchased from R&D Systems Inc. (Minneapolis, MN, USA). It is known that contamination can lead to falsely elevated serum levels. Given that MMP-9 and TIMP-1 are present in saliva, additional protective measures (protective mask) were required to prevent serum contamination during testing. Serum samples required a 10-fold dilution for TNFR1 and TNFR2, and 100-fold dilution for MMP-9 and TIMP-1 in different diluents. Polypropylene tubes were also used instead of glass tubes for sample dilution and storage. According to the manufacturer, the values of the intra-assay precision were similar to those of the inter-assay with coefficients of variation.
ranging from 4.2 to 5.4% for TNF-α, 3.6 to 5.8% for TNFR1, 2.6 to 5.1% for TNFR2, 1.9 to 7.8% for MMP-9 and 3.9 to 5.0 for TIMP-1. The MMP-9/TIMP-1, TNF-α/TNFR1 and TNF-α/TNFR2 ratios were calculated using the following formulas: MMP-9 (ng/mL)/TIMP-1 (ng/mL), TNF-α (pg/mL)/TNFR1 (pg/mL), TNF-α (pg/mL)/TNFR2 (pg/mL). Quantitative determination of serum TgAb concentrations was performed using commercial ELISA kits purchased from IBL International, Hamburg, Germany. The analytical sensitivity or the lower detection limit for TgAb was 10 IU/mL. According to the manufacturer, the values of the intra-assay precision were similar to those of the inter-assay with coefficients of variation ranging from 2.6 to 7.0% for TgAb.

The tests used in the study were 1:1 calibrated against the NIBSC/WHO 2nd International Standard 88/786 for TNF-α [24], WHO standard 65/93 for TgAb [25], the International Tg Reference Material CRM 457 (Community Bureau of Reference, BCR, European Union, Brussels, Belgium) and WHO International Standard for TSH IRP (81/565).

All assays were performed in duplicate, and in such a way as to minimize any effects of repeated freeze–thaw cycles.

2.5. Statistics

Patients’ data processing was performed using Microsoft Office Excel 2007 SP2 (including data analysis). Statistical analysis was conducted using Statistica software (version 8.0; StatSoft, Inc., Tulsa, OK, USA). The difference between the serum concentrations of different variables measured in dynamics in the two groups of patients was analyzed by the one-way ANOVA test. The results were expressed as the median (interquartile range (IQR) 25–75%). The distribution of all variables was verified with the Kolmogorov–Smirnov test. The non-parametric Kruskal–Wallis test was used to compare the distribution of continuous variables between different categories for independent samples (PTC group vs. PTC + AIT group). The Wilcoxon test was used for paired samples (PTC group, before vs. after $^{131}$I intake; PTC + AIT group, before vs. after $^{131}$I intake). The correlation between investigated biomarkers was assessed using Pearson’s correlation coefficient (r). For all tests, a $p$-value < 0.05 was considered significant.

3. Results

3.1. Clinicopathological Characteristics

No statistically significant difference was observed between the ages of the female patients enrolled in the two groups (PTC: 43.2 ± 12.7 years vs. PTC + AIT: 40.6 ± 12.3 years, $p = 0.064$).

Analysis of the pathology reports showed that the extrathyroidal extension of PTC was noticed significantly less frequently in patients with AIT: nine patients compared to 34 patients in the group without AIT ($p = 0.019$). Moreover, lymph node metastases were also observed less frequently in patients with AIT: 17 patients compared to 35 patients in the group without AIT, but this finding was not statistically significant ($p = 0.054$).

3.2. Blood Sample Radioactivity

The mean radioactivity of blood samples collected 4 days after the administration of the therapeutic dose of $^{131}$I/patient was higher in the group of patients with concomitant AIT than in the group without AIT (1.35 ± 0.09 μCi (49.95 ± 3.33 kBq)/3 mL vs. 0.25 ± 0.07 μCi (9.25 ± 2.59 kBq)/3 mL ($p < 0.001$)).

3.3. Effects of $^{131}$I Irradiation on Analyzed Biomarkers

Biochemical parameters measured in the blood samples collected before the administration of the therapeutic dose of $^{131}$I (T0) and 4 days after that (T1) from the two groups of patients (PTC and PTC + AIT) are summarized in Table 1. There was no significant difference among the groups in terms of age. In contrast, all analyzed variables were significantly higher in the PTC + AIT patients than in those with PTC at the T0 and T1 time points ($p < 0.05$), except TIMP-1 at the T1 time point ($p = 0.34$). Measurements performed
during the T1 time point revealed different $^{131}$I therapy effects in the two groups, as shown in Table 1. As a first step, $^{131}$I therapy resulted in a 17% increase in TgAb titer in patients with PTC and concurrent AIT ($p = 0.02$) and a 42% decrease in TgAb titer in patients with PTC ($p = 0.001$). In the PTC + AIT group, the TNF-α/TNFRI and TNF-α/TNFRII ratios decreased by 0.38-fold and 0.32-fold after $^{131}$I ($p = 0.001$ and $p = 0.003$, respectively) and, in the PTC group, the TNF-α/TNFRI and TNF-α/TNFRII ratios increased by 3.17-fold and 3.33-fold, respectively ($p < 0.001$).

Table 1. Biochemical parameters in the papillary thyroid cancer and papillary thyroid cancer associated with Hashimoto thyroiditis patients before and 4 days after radioiodine therapy.

| Variables | PTC | PTC + AIT |
|-----------|-----|----------|
|           | $n = 56$ | $n = 32$ |
| Age (years) | 43.2 ± 12.7 | 43.2 ± 12.7 | 40.6 ± 12.3 | 40.6 ± 12.3 |
| TgAb (IU/mL) | 7.9 (6.5–9.4) | 5.2 (3.5–7.2) | 222.7 (138.8–355.9) | 292.0 (194.0–354.4) |
| TNF-α (pg/mL) | 0.57 (0.20–0.55) | 1.3 (0.9–2.4) | 0.65 (0.35–0.90) | 0.30 (0.20–0.90) |
| TNFR1 (pg/mL) | 739.6 (664.5–906.8) | 796.2 (708.4–997.1) | 896.4 (858.8–1212.4) | 1326.9 (1051–1521.5) |
| TNFR2 (pg/mL) | 1942.9 (1527.3–2301.9) | 2102.9 (1626.7–2498.6) | 2318.5 (2116.8–2610.3) | 2542.8 (2234.7–2794.4) |
| MMP-9 (ng/mL) | 395.6 (317.4–555.5) | 300.6 (229.9–376.9) | 561.7 (351.6–798.4) | 509.4 (331.4–660.5) |
| TIMP-1 (ng/mL) | 133.2 (120.5–155.4) | 152.7 (126.5–168.7) | 154.1 (134.2–176.3) | 152.4 (141.2–180.7) |
| TNF-α/TNFRI | $4.5 \times 10^{-4}$ (3 × $10^{-4}$–7.5 × $10^{-4}$) | $16 \times 10^{-4}$ (4 × $10^{-4}$–5.8 × $10^{-4}$) | $6.1 \times 10^{-4}$ (4.3 × $10^{-4}$–10 $10^{-4}$) | $2.5 \times 10^{-4}$ (1.3 × $10^{-4}$–6.5 $10^{-4}$) |
| TNF-α/TNFRII | $2 \times 10^{-4}$ (1.3 × $10^{-4}$–2.7 $10^{-4}$) | $7 \times 10^{-4}$ (5.1 × $10^{-4}$–9.3 $10^{-4}$) | $2.7 \times 10^{-4}$ (1.6 × $10^{-4}$–4.5 $10^{-4}$) | $1.3 \times 10^{-4}$ (0.7 × $10^{-4}$–3.5 $10^{-4}$) |
| MMP-9/TIMP-1 | 3.1 (2.4–3.7) | 1.8 (1.3–2.5) | 3.7 (2.1–4.9) | 3.2 (2.2–4.4) |

MMP-9, matrix metalloproteinase-9; PTC, papillary thyroid cancer; PTC + AIT, papillary thyroid cancer associated with autoimmune thyroiditis; TgAb, anti-thyroglobulin antibodies; TIMP-1, tissue inhibitor of metalloproteinase-1; TNF-α, tumor necrosis factor-α; TNFR1, TNF receptor type 1; TNFR2, TNF receptor type 2. a Mean ± standard deviation. b Data are expressed as median values and interquartile ranges (25–75%). c PTC group (T0) vs. PTC + AIT group (T0): $p < 0.05$. d PTC group (T1) vs. PTC + AIT group (T1): $p < 0.05$ (except TIMP-1 with no statistical significance).

3.4. Correlations

Scatter plots shown in Figure 1 indicate a close relationship between TgAb and TNFR1 ($r = 0.42$, $p = 0.016$), MMP-9 ($r = 0.44$, $p = 0.01$) and the MMP-9/TIMP-1 ratio ($r = 0.57$, $p < 0.001$) in patients with PTC and concomitant AIT.

![Figure 1](image-url)

Figure 1. Correlations between serum concentrations of TgAb and TNFR1 (A), MMP-9 (B), MMP-9/TIMP-1 ratio (C) in patients with papillary thyroid cancer associated with autoimmune thyroiditis.

Moreover, the TNF-α/TNFRI and TNF-α/TNFRII ratios were positively correlated with the MMP-9/TIMP-1 ratio both before and 4 days after $^{131}$I administration (Figure 2A (T0): $r_{TNF-\alpha/TNFRI-MMP-9/TIMP-1} = 0.59$, $p < 0.001$; Figure 2B (T1): $r_{TNF-\alpha/TNFRI-MMP-9/TIMP-1} = 0.48$, $p = 0.005$ and Figure 3A (T0): $r_{TNF-\alpha/TNFRII-MMP-9/TIMP-1} = 0.63$, $p < 0.001$; Figure 3B (T1): $r_{TNF-\alpha/TNFRII-MMP-9/TIMP-1} = 0.46$, $p = 0.007$).
Figure 1. Correlations between serum concentrations of TgAb and TNFR1 (A), MMP-9 (B), MMP-9/TIMP-1 ratio (C) in patients with papillary thyroid cancer associated with autoimmune thyroiditis.

Moreover, the TNF-α/TNFR1 and TNF-α/TNFR2 ratios were positively correlated with the MMP-9/TIMP-1 ratio both before and 4 days after 131I administration (Figure 2A (T0): $r_{\text{TNF-}\alpha/\text{TNFR1-MMP-9/TIMP-1}} = 0.59$, $p < 0.001$; Figure 2B (T1): $r_{\text{TNF-}\alpha/\text{TNFR1-MMP-9/TIMP-1}} = 0.48$, $p = 0.005$ and Figure 3A (T0): $r_{\text{TNF-}\alpha/\text{TNFR2-MMP-9/TIMP-1}} = 0.63$, $p < 0.001$; Figure 3B (T1): $r_{\text{TNF-}\alpha/\text{TNFR2-MMP-9/TIMP-1}} = 0.46$, $p = 0.007$).

Figure 2. Correlations between MMP-9/TIMP-1 ratio and TNF-α/TNFR1 ratio measured before 131I intake (A) and at 4 days after 131I intake (B) in patients with papillary thyroid cancer associated with autoimmune thyroiditis.

Figure 3. Correlations between MMP-9/TIMP-1 ratio and TNF-α/TNFR2 ratio measured before 131I intake (A) and at 4 days after 131I intake (B) in patients with papillary thyroid cancer associated with autoimmune thyroiditis.

In contrast to patients with concomitant AIT, in the PTC group, TNF-α/TNFR1 and TNF-α/TNFR2 ratios were negatively correlated with the MMP-9/TIMP-1 ratio only after 131I therapy (T1: $r_{\text{TNF-}\alpha/\text{TNFR1-MMP-9/TIMP-1}} = -0.62$, $p < 0.001$, $r_{\text{TNF-}\alpha/\text{TNFR2-MMP-9/TIMP-1}} = -0.58$, $p < 0.001$), as shown in Figure 4A,B.
4. Discussion

$^{131}$I therapy after total thyroidectomy is an integral part of loco-regional therapy for well-differentiated thyroid cancer. $^{131}$I therapy, as cancer-targeted radiotherapy, can mobilize the host’s immune effector mechanisms that involve both pro-immunogenic and immunosuppressive effects. TgAbs are produced by B lymphocytes, and are considered to be more radiosensitive than T lymphocytes, with a decrease in serum titers after irradiation of 33–90% [26]. In our study, the decline in low-TgAb levels in patients with PTC without AIT was 42%, a percentage that falls within the statistics published to date for B lymphocytes. Unlike the PTC group, in patients with concomitant AIT, $^{131}$I intake led to a 17% increase in circulating TgAb levels. Our results show that in the presence of high titers of TgAb, the effect of $^{131}$I is no longer immunosuppressive. The direct effect of a high dose of irradiation is to stimulate the production of B lymphocytes to the detriment of T lymphocytes. As mentioned previously, TgAbs are antibodies produced by B lymphocytes that originate in the bone marrow, mature in the spleen and differentiate into lymph nodes after contact with antigens and T cells and different cytokines. Moreover, the radioactivity of blood samples collected from patients with elevated concentrations of TgAb was higher than that of samples collected from patients with low TgAb levels (1.35 ± 0.09 µCi (49.95 ± 3.33 kBq)/3 mL vs. 0.25 ± 0.07 µCi (9.25 ± 2.59 kBq)/3 mL ($p < 0.001$)). Increased blood radioactivity measured 4 days after the administration of the therapeutic dose of $^{131}$I indicates a low $^{131}$I uptake in PTC + AIT patients. Our results are consistent with those obtained by Lim et al. [8], who showed in a retrospective cohort study that the patients with AIT were significantly more likely to have low or no $^{131}$I uptake, demonstrated on the post-ablation scan.

It is known that $^{131}$I uptake is influenced by several factors, such as (i) the age of the patient; (ii) the volume of the functional thyroid remnant; (iii) renal clearance; (iv) the iodinated substances (amiodarone, intravenous contrast agents, iodine-containing medicines and preparations); (v) thyroid medications (levothyroxine, liothyronine, anti-thyroid drugs—methimazole, carbimazole); (vi) iodine-containing food. Some of these interfering factors were eliminated through a prior $^{131}$I low-iodine diet, following the guidelines for $^{131}$I therapy of differentiated thyroid cancer [16,17]. Regarding the age of the patients enrolled in the study, it should be mentioned that the study groups (PTC and PTC + AIT) matched. Our results showed that PTC + AIT patients had a lower rate of extrathyroidal extension and a non-significant reduction in lymph node metastasis than PTC patients [8,27]. These findings may lead to the idea that the volume of the functional thyroid remnant is lower in the PTC + AIT group than in the PTC group, partially explain-
ing the low $^{131}$I uptake in patients with concomitant AIT. Our specific aim was to find the mechanisms that govern immune cells during $^{131}$I therapy of PTC + AIT patients, rather than the success of long-term ablation, which is beyond the scope of this paper. Therefore, we did not review the degree of extrathyroidal uptake seen on the post-ablation. Another factor that could influence the $^{131}$I uptake and should be considered could be the increased titers of TgAb. Detailed studies are needed to debate this subject.

When $^{131}$I accumulates in the remnant thyroid tissue, its decay results in thyroid cancer cells’ high energy deposition and minimal irradiation of the surrounding normal tissues. The expression of TNF-α and TIMP-1 is increased after irradiation [12,13,28] and can be involved in the $^{131}$I-induced bystander effect. Similar to the previously mentioned studies [12,13,28], our results showed that $^{131}$I intake led to a 3.55-fold increase in TNF-α and a 1.19-fold in TIMP-1 in patients without AIT. Moreover, the involvement of TNF-α and the MMP-9/TIMP-1 complex in the radiation-induced non-targeted effects has been demonstrated by the highly statistically significant correlations measured between TNF-α and TIMP-1 ($r = 0.68, p < 0.001$) and TNF-α and the MMP-9/TIMP-1 ratio ($r = -0.66, p < 0.001$). Instead, in the presence of AIT, TNF-α decreased with a median value of 31% and TIMP-1 remained unchanged, with the two parameters not being statistically correlated. TNF-α has been shown to have a dual role with opposite effects on tumor development: at low concentrations, TNF-α promotes angiogenesis and metastasis of tumor cells, and at high levels has antitumor effects [29]. It seems that TNF-α and the MMP-9/TIMP-1 complex work together with $^{131}$I targeted therapy. The involvement of the TNF-α and MMP-9/TIMP-1 complex in radiation-induced non-targeted effects led to the inhibition of tumor angiogenesis, highlighted by the 0.34-fold decrease in the MMP-9/TIMP-1 ratio in patients without AIT, which was only 0.8-fold in patients with coexisting AIT.

In response to high-dose irradiation, in our case, irradiation with an average dose of 100 mCi (3.7 GBq)/patient, TNF-α precursor is slowly cleaved from the cell surface by MMPs, producing soluble TNF-α, which can increase apoptosis by binding to TNFRI [15]. TNFRI signaling contributes to the pathological processes of autoimmune disorders, promoting, on the one side, inflammation in AIT [30] and, on the other side, being a key factor in the tumor microenvironment, the $^{131}$I apoptotic response. As a confirmation, our results showed a statistically significant correlation between TgAb and TNFRI ($r = 0.42, p = 0.016$), MMP-9 ($r = 0.44, p = 0.01$) and the MMP-9/TIMP-1 ratio ($r = 0.57, p < 0.001$) in patients with PTC and concomitant AIT. Conversely, TNFRI is mainly limited to immune and endothelial cells, supporting the regulatory T cells’ function [31].

In the PTC group, $^{131}$I intake led to an increase in the TNF-α/TNFRI and TNF-α/TNFRI ratios (by 3.17-fold and 3.33-fold), with these increases being negatively correlated with the MMP-9/TIMP-1 ratio ($r_{\text{TNF-α/TNFRI-MMP-9/TIMP-1}} = -0.62, p < 0.001$, $r_{\text{TNF-α/TNFRI-MMP-9/TIMP-1}} = -0.58, p < 0.001$) (Figure 4). Unlike the PTC group, in the presence of concomitant AIT, $^{131}$I intake led to a decline in the TNF-α/TNFRI and TNF-α/TNFRI ratios (by 0.38-fold and 0.32-fold, respectively), with these decreases being positively correlated with the MMP-9/TIMP-1 ratio ($r_{\text{TNF-α/TNFRI-MMP-9/TIMP-1}} = 0.48, p = 0.005$, $r_{\text{TNF-α/TNFRI-MMP-9/TIMP-1}} = 0.46, p = 0.007$) (Figures 2B and 3B). It should be noted that prior to irradiation in the PTC + AIT group, there was a strong correlation between TNF-α/TNFRI, TNF-α/TNFRI2 and MMP-9/TIMP-1 ($r_{\text{TNF-α/TNFRI-MMP-9/TIMP-1}} = 0.59, p < 0.001$, $r_{\text{TNF-α/TNFRI2-MMP-9/TIMP-1}} = 0.63, p < 0.001$) (Figure 3A,B), while in the group without AIT, there was no correlation between these parameters.

The most apparent weakness of our study is related to the small number of patients included. Despite the small sample size, the two study groups matched in terms of number, gender distribution and age.

Considering the immune response to $^{131}$I therapy, the two groups of patients can be seen as mirror images of each other. In this regard, in patients with PTC, $^{131}$I therapy modulates the production of cytokines in situ, increasing the antitumor immune response accordingly. On the contrary, in the context of the existence of chronic inflammation due to
to AIT, $^{131}$I therapy amplifies innate immunity and leads to a weaker development of adaptive, specific immunity.

Elevated TNF-α/TNFFR1 and TNF-α/TNFFR2 ratios indicate a decline in disease activity after $^{131}$I therapy, which is more pronounced in PTC than in PTC + AIT, suggesting that suppression of TNFR1 and TNFR2 or increased production of TNF-α is required to initiate remission of cancer. In PTC patients, $^{131}$I therapy almost halved the imbalance between MMP-9 and TIMP-1 and this decrease may reduce tumor cell viability and migratory potential.

Our results demonstrate that the same mediator, in this case, TNF-α, may exert different antitumor effects in response to $^{131}$I therapy depending on the patient’s immune profile and, therefore, in a clinical setting, may represent a double-edged sword. Certainly, more information is needed before drawing firm conclusions about the non-targeted effects induced by $^{131}$I in PTC patients with/without AIT.

Author Contributions: Conceptualization, A.E.S.; methodology, A.E.S. and A.Z.; formal analysis, M.M.S.; investigation, A.E.S. and A.Z.; data curation, M.M.S. and A.E.S.; writing—original draft preparation, A.E.S.; writing—review and editing, D.C.G., M.M.S., A.Z. and A.E.S.; visualization, A.E.S. and A.Z.; supervision, A.E.S.; project administration, A.E.S.; funding acquisition, A.E.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by a grant from the Romanian Ministry of Education and Research, CCCDI-UEFISCDI, project number PN-III-P2-2.1-PED-2019-3313, within PNCDI III.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institute of Oncology Bucharest Medical Ethics Committee (No.15140/10.09.2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Lerner, A.; Jeremias, P.; Matthias, T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. Int. J. Celiac Dis. 2015, 3, 151–155. [CrossRef]
2. Valencia, J.C.; Egbukichi, N.; Ervin-Cohen, R.A. Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity. J. Interferon Cytokine Res. 2019, 39, 72–84. [CrossRef]
3. Trovato, M.; Giuffrida, G.; Seminara, A.; Fogliani, S.; Cavallari, V.; Ruggeri, R.M.; Campennì, A. Coexistence of diffuse large B-cell lymphoma and papillary thyroid carcinoma in a patient affected by Hashimoto’s thyroiditis. Arch. Endocrinol. Metab. 2017, 61, 643–646. [CrossRef]
4. Lee, J.H.; Kim, Y.; Choi, J.W.; Kim, Y.S. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: A meta-analysis. Eur. J. Endocrinol. 2013, 168, 343–349. [CrossRef]
5. Jeong, J.S.; Kim, H.K.; Lee, C.R.; Park, S.; Park, J.H.; Kang, S.W.; Jeong, J.J.; Nam, K.H.; Chung, W.Y.; Park, C.S. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: Clinical manifestation and prognostic outcome. J. Korean Med. Sci. 2012, 27, 883–889. [CrossRef]
6. Stanciu, A.E. Cytokines in heart failure. Adv. Clin. Chem. 2019, 93, 63–113. [CrossRef]
7. Lun, Y.; Wu, X.; Xia, Q.; Han, Y.; Zhang, X.; Liu, Z.; Wang, F.; Duan, Z.; Xin, S.; Zhang, J. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer: Clinical manifestation and prognostic outcome. Endocr. Connect. 2019, 8, 571–578. [CrossRef]
8. Lim, E.; Shah, S.; Waterhouse, M.; Akker, S.; Drake, W.; Plowman, N.; Berney, D.M.; Richards, P.; Adams, A.; Nowosinska, E.; et al. Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer. Endocr. Connect. 2019, 8, 571–578. [CrossRef]
9. Frey, B.; Rubner, Y.; Kulzer, L.; Werthmüller, N.; Weiss, E.M.; Fietkau, R.; Gaip!, U.S. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol. Immunother. 2014, 63, 29–36. [CrossRef]
10. Menon, H.; Ramapriyan, R.; Cushman, T.R.; Verma, V.; Kim, H.H.; Schoenhals, J.E.; Atalar, C.; Selek, U.; Chun, S.G.; Chang, J.Y.; et al. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front. Immunol. 2019, 10, 193. [CrossRef]
11. Pouget, J.P.; Georgakilas, A.G.; Ravanat, J.L. Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. Antioxid. Redox Signal. 2018, 29, 1447–1487. [CrossRef]

12. Wang, R.; Zhou, T.; Liu, W.; Zuo, L. Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy. Oncotarget 2018, 9, 18637–18647. [CrossRef]

13. Widel, M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy? Neoplasma 2017, 64, 641–654. [CrossRef]

14. Palata, O.; Hradilova Podzimkova, N.; Nedvedova, E.; Umprecht, A.; Sadilkova, L.; Palova Jelinkova, L.; Spisek, R.; Adkins, I. Radiotherapy in Combination with Cytokine Treatment. Front. Oncol. 2019, 9, 367. [CrossRef]

15. Fischer, R.; Kontermann, R.E.; Pfizenmaier, K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Front. Cell Dev. Biol. 2020, 8, 401. [CrossRef]

16. Fugazzola, L.; Elisei, R.; Fuhrer, D.; Jarzab, B.; Leboulleux, S.; Newbold, K.; Smit, J. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioidine-Refractory Thyroid Cancer. Eur. Thyroid J. 2019, 8, 227–245. [CrossRef]

17. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [CrossRef]

18. Sisson, J.C.; Freitas, J.; McDougall, I.R.; Dauer, L.T.; Hurley, J.R.; Brierley, J.D.; Edinboro, C.H.; Rosenthal, D.; Thomas, M.J.; Wexler, J.A.; et al. Radiation safety in the treatment of patients with thyroid diseases by radioidine 131I: Practice recommendations of the American Thyroid Association, The American Thyroid Association Taskforce on Radioiodine Safety. Thyroid 2011, 21, 335–346. [CrossRef]

19. Stanciu, A.E.; Zamfir-Chiru-Anton, A.; Stanciu, M.M.; Stoian, A.P.; Jinga, V.; Nitipir, C.; Pituru, T.S.; Arsene, A.L.; Dragoi, C.M.; et al. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncol. Lett. 2020, 19, 1537–1543. [CrossRef]

20. Trovato, M. A historical excursus of diagnostic methods for Hashimoto thyroiditis and Graves’ disease. Gazz. Med. Ital. Arch. Sci. Med. 2019, 179, 479–485. [CrossRef]

21. Mohamed, S.Y.; Ibrahim, T.R.; Elbasateeny, S.S.; Abdelaziz, L.A.; Farouk, S.; Yassin, M.A.; Embaby, A. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis. Sci. Rep. 2020, 10, 10651. [CrossRef]

22. Casella, C.; Ministrini, S.; Galani, A.; Mastriale, F.; Cappelli, C.; Portolani, N. The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging. Front. Endocrinol. 2018, 9, 541. [CrossRef]

23. Lassmann, M.; Hanscheid, H.; Chiesa, C.; Hindorf, C.; Flux, G.; Luster, M.; EANM Dosimetry Committee. EANM Dosimetry Committee series on standard operational procedures for pretherapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1405–1412. [CrossRef] [PubMed]

24. WHO International Standard Tumour Necrosis Factor Alpha (Human, Natural). Available online: https://www.nibsc.org/documents/ifu/88-786.pdf (accessed on 6 May 2021).

25. Feldt-Rasmussen, U.; Profils, C.; Colinet, E.; Black, E.; Bornet, H.; Bourdoux, P.; Carayon, P.; Ericsson, U.B.; Koutras, D.A.; Lamas de Leon, L.; et al. Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification. Ann. Biol. Clin. 1996, 54, 343–348.

26. Swanson, G.P.; Jhavar, S.G.; Hammonds, K. The effect of pelvic radiation alone on lymphocyte subgroups. Clin. Transl. Radiat. Oncol. 2020, 23, 100–102. [CrossRef]

27. Girardi, F.M.; Barra, M.B.; Zettler, C.G. Papillary thyroid carcinoma: Does the association with Hashimoto’s thyroiditis affect the clinicopathological characteristics of the disease? Braz. J. Otorhinolaryngol. 2015, 81, 283–287. [CrossRef] [PubMed]

28. Widel, M. Radiation induced bystander effect: From in vitro studies to clinical application. Int. J. Med. Phys. Clin. Eng. Radiat. Oncol. 2016, 5, 63298. [CrossRef]

29. Lumniczky, K.; Sáfrány, G. The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences. Cancer Lett. 2015, 356, 114–125. [CrossRef] [PubMed]

30. Saddala, M.S.; Huang, H. Identification of novel inhibitors for TNFα, TNFR1 and TNFα-TNFR1 complex using pharmacophore-based approaches. J. Transl. Med. 2019, 17, 215. [CrossRef]

31. Pegoretti, V.; Baron, W.; Laman, J.D.; Eiselt, U.L.M. Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment. Front. Immunol. 2018, 9, 925. [CrossRef]